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Abstract
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain 
cancer cell growth and proliferation1,2. Here we show that mTORC1 regulates polyamine 
dynamics, a metabolic route that is essential for oncogenicity. Through the use of integrative 
metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identified 
alterations in tumours impacting on the production of decarboxylated S-adenosylmethionine 
(dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from 
mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This 
novel molecular regulation was validated in murine and human cancer specimens. AMD1 was 
upregulated in prostate cancer specimens with activated mTORC1. Conversely, samples from a 
clinical trial with the mTORC1 inhibitor everolimus5 exhibited a predominant decrease in AMD1 
immunoreactivity that was associated to a decrease in proliferation, in line with the requirement of 
dcSAM production for oncogenicity. These findings provide fundamental information about the 
complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals 
into an oncogenic metabolic program.
Alterations in the Phosphoinositide-3 kinase (PI3K) pathway have been reported in a high 
percentage of human cancers6,7. We sought to identify metabolic requirements of prostate 
cancer (PCa) taking advantage of a faithful genetically engineered mouse model (GEMM) of 
this disease driven by loss of Pten3, a negative regulator of the PI3K pathway that is 
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frequently down-regulated in PCa6,8. First, we carried out high-throughput Time-Of-Flight 
mass spectrometry (TOF-MS) to examine metabolic alterations at two time points (3 and 6 
months, onset of prostate intraepithelial neoplasia (PIN) and invasive prostate carcinoma, 
respectively) (Extended data Fig. 1a, b) in two different prostate lobes (Extended data Fig. 
1c). From 7722 ions, we assigned metabolite identification (Human Metabolome Database 
(HMDB) score ≥ 40) to 632 (Supplementary Table 1). We did not observe significant 
influence of the prostate lobe or the time point of analysis, and after precluding significant 
alterations in candidate metabolic pathways, we focused on metabolites consistently altered 
in all conditions (Extended data Fig. 1d, e; Supplementary Table 2). We identified 72 unique 
metabolites (73 assigned ions) fulfilling the criteria (Fig. 1a; Supplementary Table 1). 
Pathway enrichment analysis in this set did not show significantly altered pathways 
including a considerable number of metabolites (Supplementary Table 3). Strikingly, we 
observed an increase in polyamine synthesis-related metabolites in Ptenpc-/- mice (Fig. 1b). 
These results were validated in mouse GEMM and human PCa tissues by quantitative Liquid 
Chromatography (LC)/MS (Extended data Fig. 1f, g; Supplementary Table 4).
In order to determine how metabolic rewiring affects polyamine dynamics, we set up 13C-
labelling metabolic analysis to trace the fate of methionine-derived carbons in vivo 
(Extended data Fig. 2a). Next, we injected U-13C5-methionine intravenously in Ptenpc+/+ and 
Ptenpc-/- mice (Extended data Fig. 2b). Prostate tissue analysis revealed an elevation in 13C-
labelled decarboxylated S-adenosylmethionine (dcSAM), together with increased synthesis 
and fractional labelling of polyamines (Fig. 1c; Extended data Fig. 2c, d; Supplementary 
Table 5). Importantly, the increase of S-adenosylmethionine (SAM) decarboxylation 
(elevated dcSAM/SAM ratio) in both mouse and human pathological tissue strongly 
suggested that the enzyme which catalyses this reaction (S-adenosylmethionine 
decarboxylase 1, AMD1) is potentially responsible for the metabolic changes observed in 
PCa (Fig. 1d-f).
To address the contribution of dcSAM production to PCa cell oncogenicity, we ectopically 
expressed AMD1 in PCa cell lines. AMD1 is produced as a pro-enzyme, that is subject to 
self-cleavage and heterotetramerization, resulting in the active enzyme9. After validation of 
a polyclonal antibody for the detection of proAMD1 and AMD1 (Extended data Fig. 3a, b), 
we generated PCa cells in which the expression of AMD1 was up-regulated, which resulted 
in increased dcSAM abundance (Fig. 2a, b). Interestingly, this perturbation increased foci 
formation, anchorage-independent growth and in vivo tumour growth (Fig. 2c, d; Extended 
data Fig. 3c-f).
If AMD1 activity is essential for PCa cell function, targeting this enzyme would represent an 
attractive therapeutic strategy. To test this notion, we generated and validated three AMD1-
targeting doxycycline-inducible and two constitutive shRNAs (Fig. 2e; Extended data Fig.
3g-j), that resulted in a profound reduction in dcSAM levels, the inhibition of two-
dimensional and anchorage-independent growth, and tumour growth in vivo (Fig. 2f-h; 
Extended data Fig. 3k-t). We excluded doxycycline-dependent (Extended data Fig. 3u, v) 
and off-target effects of the shRNA (by means of ectopic expression of shRNA-resistant 
wild-type – WT - or non-processable - S229A10 - AMD1 mutants) (Extended data Fig. 4a-
c). Of note, we did not observe a contribution of MTAP11–14 nor 5´-Methylthioadenosine 
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(MTA, a product of dcSAM metabolism to produce polyamines) to the effect of AMD1 
inhibition (Extended data Fig. 4d-f).
A pharmacological inhibitor of AMD1, SAM486A, has been designed and evaluated in pre-
clinical and clinical settings15–18. Pharmacological AMD1 inhibition recapitulated the 
biological consequences of genetic silencing, in the absence of overt toxicity in vivo (Fig. 2i-
k; Extended data Fig. 4g-k; Supplementary Table 6). Our results collectively demonstrate 
that AMD1 activity is required for PCa oncogenicity.
We next sought to elucidate the mechanism underlying the production of dcSAM. 
Interestingly, AMD1 protein levels were increased in prostate tissue from Ptenpc-/- mice in 
the absence of transcriptional modulation, consistent with mRNA analysis in human PCa 
datasets (Fig. 3a; Extended data Fig. 5a-c). To ascertain whether this phenotype was a direct 
consequence of the loss of PTEN, we analysed PTEN-deficient PCa cells (LNCaP). Re-
expression of YFP-PTENWT, but not catalytically inactive YFP-PTENC124S, in these cells 
resulted in the reduction in AMD1 protein levels (Extended data Fig. 5d)19. Further 
dissection of the PI3K-mTORC1 pathway revealed that only mTORC1 blockers among 
various signalling inhibitors decreased proAMD1 and AMD1 protein abundance (without 
consistent effects on mRNA expression; Fig. 3b; Extended data Fig. 5e-h). The regulation of 
this enzyme by mTORC1 was validated upon genetic modulation of positive and negative 
regulators of the complex, RAPTOR and TSC2, respectively (Extended data Fig. 5e, i, j). 
Importantly, mTORC1 inhibitor-elicited AMD1 down-regulation was accompanied by a 
decrease in dcSAM production and polyamine synthesis (Fig. 3c, d). Of interest, spermidine 
(Spd) supplementation in rapamycin-treated PC3 cells (PTEN-deficient) elicited a 
significant (albeit small) increase in cell number (Extended data Fig. 6a).
In order to ascertain the requirement of mTORC1 activation for dcSAM accumulation in 
vivo, we treated Ptenpc-/- mice with the rapamycin-derivative RAD001 and found that Amd1 
and dcSAM abundance was reduced in line with the inhibition of mTORC1 in prostate tissue 
(Fig. 3e, f; Extended data Fig. 6b, c). Of note, a second PCa GEMM based on the expression 
of the TRAMP transgene20, which presented low mTORC1 activation, did not exhibit an 
increase in Amd1 nor dcSAM abundance, in support of our postulated mTORC1-AMD1 
regulation (Extended data Fig. 6d, e; Supplementary Table 7).
Mechanistically, we excluded the contribution of ornithine decarboxylase 121 (ODC1; 
Extended data Fig. 7a-e) and canonical mTORC1 downstream effectors and 
pathways1,22,23, including translation initiation, p70S6K, 4EBP and macro-autophagy 
(since DU145 cells lack functional ATG524 but retain the mTORC1-dependent regulation of 
AMD1) (Extended data Fig. 7f-i). Interestingly, we found that mTORC1 inhibition-
dependent decrease in AMD1 (WT and S229A) protein levels was rescued by the 
proteasome inhibitor MG132 (Fig. 4a; Extended data Fig. 8a, b). To elucidate the molecular 
link between mTORC1 activity and proAMD1 stability, we carried out a phosphoproteomic 
analysis on ectopic proAMD1/AMD1 and identified a single phosphorylated residue (S298) 
on the pro-enzyme and enzyme (TVLApSPQKIEGFK) (Extended data Fig.8c) that was 
compatible with a consensus mTORC1 site25. Importantly, 6-hour treatment with rapamycin 
or Torin-1 reduced the phosphorylation of S298 in the pro-enzyme (and the ratio phospho-
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proAMD1/total proAMD1) but not the enzyme, leading us to hypothesize that S298 
phosphorylation is controlled by mTORC1 and promotes proAMD1 stability (Fig. 4b and 
Extended data Fig. 8d-f). We evaluated the stability of proAMD1 after a 2 hour treatment 
with Torin-1 (prior to the detection of any effect on pro-enzyme abundance) and found 
reduced half-life upon mTORC1 inhibition (Extended data Fig. 8g-k). To establish the 
contribution of S298 phosphorylation in the regulation of proAMD1 stability, we inactivated 
this phosphorylation site (S298A). As predicted, non-phosphorylated proAMD1S298A 
exhibited decreased half-life, and this parameter was augmented upon inhibition of the 
proteasome (Extended data Fig. 9a-c). These results support the notion that mTORC1 
activity promotes proAMD1 stability, at least in part, through the regulation of its 
phosphorylation in S298, hence allowing enzyme processing and activity. In vitro mTORC1 
kinase assay with GST-proAMD1S229A did not show significant activity towards proAMD1 
phosphorylation in these conditions, suggesting either that mTORC1 does not directly 
phosphorylate S298, or that additional cellular conditions (e.g. biochemical conditions, 
adaptor or intermediary proteins, sub-cellular compartments) are required for mTORC1 to 
phosphorylate proAMD1 (Extended data Fig. 9d). It is worth noting that our data does not 
rule out additional mechanisms downstream mTORC1 regulating proteasome-mediated 
protein degradation23,26. In order to extend this mechanistic link to human PCa, we 
extracted protein from well-diagnosed benign prostate hyperplasia (BPH) and PCa 
specimens4 (Supplementary Table 4). The results revealed that AMD1 was selectively more 
abundant in PCa specimens exhibiting high mTORC1 activity, and that the phosphorylation 
of p70S6K significantly correlated with the levels of AMD1 (correlation coefficient R 
=0.81; Fig. 4c; Extended data Fig. 9e).
mTORC1 inhibitors are currently used to treat certain tumours (despite the unpredicted 
inefficacy in many others)27, and prior work by us contributed to define the pharmaco-
dynamic properties of everolimus in individuals with advanced cancers of different 
origin5,28,29. Strikingly, we observed a predominant decrease in AMD1 immunoreactivity 
in 14 biopsies obtained from patients treated with this drug relative to a biopsy of the same 
lesion prior to treatment (Fig. 4d; Extended data Fig. 9f; Supplementary Table 8). When we 
stratified patients on the basis of the anti-proliferative response achieved after everolimus 
therapy (responders: differential KI67 H-score: ΔH < 0, n = 6 specimen pairs; non-
responders: differential KI67 H-score: ΔH ≥ 0, n = 4 specimen pairs), we found that only 
AMD1 (among all targets analysed) presented significantly decreased immunoreactivity in 
responders (Fig. 4e; Extended data Fig. 9g).
Polyamine production is a hallmark of highly proliferating cells30, but their regulation by 
oncogenic signals remains largely unknown. Our results demonstrate that increased 
polyamine synthesis is associated to oncogenic signalling in PCa. The regulation of AMD1 
production and dcSAM synthesis downstream mTORC1 described herein provides a 
mechanistic explanation for the control of this metabolic program (Extended data Fig. 9h). 
AMD1 is an unprecedented metabolic target of this protein complex and supports its role in 
cancer cell proliferation. Importantly, the control of dcSAM and polyamine synthesis is 
relevant beyond the cancer scenario, and suggests that physiological and developmental 
processes that require active cell proliferation might be tightly associated to the regulation of 
AMD1 and polyamine synthesis downstream of mTORC1.
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Methods
Patient samples
All prostate specimens were obtained upon informed consent and with evaluation and 
approval from the corresponding ethics committee (CEIC code OHEUN11-12 and 
OHEUN14-14)4. A table providing clinic-pathological information is included as 
Supplementary Table 4. The details of the clinical trial with everolimus are described in Ref. 
5 and in Supplementary Table 8.
Animals
All mouse experiments were carried out following the ethical guidelines established by the 
Biosafety and Animal Welfare Committee at CIC bioGUNE (under protocol P-CBG-
CBBA-0715). The procedures employed were carried out following the recommendations 
from AAALAC. Xenograft experiments were performed as previously described (maximum 
total tumour volume per mouse 1.5 cm3)31, injecting 4x106 (AMD1 silencing) or 4x106 
(AMD1 ectopic expression) cells with Matrigel (BD Biosciences) per condition in two 
flanks per mouse. GEMM experiments were carried out in a mixed background as 
reported32. The Ptenlox conditional knockout allele has been described elsewhere3. Prostate 
epithelium-specific deletion was effected by the Pb-Cre43. Mice were fasted for 6h prior to 
tissue harvest (9am-3pm) in order to prevent metabolic alterations due to immediate food 
intake. The TRAMP mice string was originally obtained from The Jackson Laboratory 
repository. Animals were maintained at the Animal Facility (awarded with the AAALAC 
accreditation) of the Spanish National Cancer Research Centre (CNIO) in accordance with 
the guidelines stated in the International Guiding Principles for Biomedical Research 
Involving Animals, developed by the Council for International Organizations of Medical 
Sciences (CIOMS). All animal experiments were approved by the Competent Authority of 
the Comunidad de Madrid. The generation and characterisation of TRAMP mice was have 
been previously described20. At CNIO TRAMP mice originally provided in FVB/NJ genetic 
background were backcrossed to a C57BL/6 background by successive mating of (T/+) 
male-mice to (+/+) C57BL/6 female-mice and then maintained in a C57BL/6 background.
To address the potential undesirable effects of systemic AMD1 inhibition, we administered 
intraperitoneally SAM486A (5mg/Kg/day, 5-days per week) for 17 days in 
immunocompetent C57BL/6 mice. We measured body and organ weight, blood 
biochemistry, haematocrit and white blood cell count (information provided in 
Supplementary Table 6). Terminal blood harvest was performed intracardially after CO2-
inhalation based euthanasia. For non-terminal harvest, a facial vein blood sample was 
obtained by puncture with a sterile 4 mm lancet (MEDIpoint Inc., USA). For plasma 
preparation, blood was deposited in tubes with Dipotassium EDTA (Microtainer®, Becton-
Dickinson, Franklin, NJ, USA) (for haematocrit and FACS analysis) or heparinized tubes 
(10 µL,1 U/µL) (for plasma metabolomics). For haematocrit analysis blood samples were 
analysed using an Abacus Junior Vet analyser (Diatron, Hungary) according to 
manufacturers´ guidelines. For blood biochemistry, a Selectra Junior Spinlab 100 analyser 
(Vital Scientific, Dieren, The Netherlands) was employed. A calibrated control was run 
before each use and was within established ranges prior to analysing samples. For white 
Zabala-Letona et al. Page 5
Nature. Author manuscript; available in PMC 2017 December 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
blood cell analysis, the spleen of SAM486A or saline-treated mice was grinded using a 
syringe plunger and passing the cells through a 70 µm cell strainer, and cellular composition 
was evaluated by flow cytometry, using the following antibodies: CD4, CD8, B220, Ly6C, 
F4/80, GR-1, CD25, CD11b, CD44, CD73, FR4, Nrp-1 (Miltenyi Biotec).
Purification and activation of murine splenic CD4+ T cells
In order to address the toxicity of SAM486A, we purified CD4 T cells from the spleen of 
C57BL/6 mice by negative selection using the CD4 purification kit following the 
manufacturer´s instructions (Miltenyi Biotec, Auburn, CA). 5 × 105 CD4 T cells were 
activated in TexMACS Medium (Miltenyi Biotec) with plate-bound anti-CD3 (5 µg/mL) and 
soluble anti-CD28 (1 µg/mL) in the presence of vehicle or SAM486A (1µM) for 16 and 96 h 
and assessed for IL-2 production by capture ELISA (R&D Systems, MAB702). To analyse 
the effect of SAM486A on T cell proliferation, purified CD4 T cells were recovered 4 days 
after activation and treatment and counted in a hemocytometer chamber.
Immunization with ovalbumin
To address the effect of SAM486A on immune cell proliferation in vivo, potential we 
administered intraperitoneally SAM486A (5 mg/Kg/day, 5-days per week) for 17 days in 
immunocompetent C57BL/6 mice, and then immunized them subcutaneously 2 weeks later 
with 50 µg of ovalbumin (OVA) in Complete Freund´s adjuvant and kept on treatment. After 
2 weeks, the mice were analysed for ovalbumin-specific serum IgG and IgM levels by 
ELISA33.
Reagents
Cell lines were purchased from Leibniz-Institut DSMZ - Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (DSMZ) and tested negative for mycoplasma. An 
authentication certificate was provided by DSMZ for cell lines. Rapamycin (prepared in 
DMSO, final concentration 20 nM), Torin-1 (prepared in DMSO, final concentration 
125-250 nM), Dimethylfluorornithine (DFMO, prepared in water, final concentration 50 
µM), PF-4708671 (PF47, prepared in DMSO, final concentration 10 µM) 
Hydroxychloroquine (HCQ, prepared in water, final concentration 30 ng/mL), MG132 (5 
µM, prepared in DMSO), PD0325901 (100 nM, prepared in DMSO), SB203580 (5 µM, 
prepared in DMSO), SP600125 (10 µM, prepared in DMSO), Spermidine (Spd, 0.5-1 µM, 
prepared in water), 5'-Deoxy-5'-(methylthio)adenosine (MTA) and cycloheximide (CHX, 
prepared in ethanol, final concentration 5 µg/mL) were purchased from LC laboratories 
(Rapamycin), Sigma (CHX, PF47, HCQ, Spd, MTA), Calbiochem (SB203580) and Tocris 
(Torin-1, DFMO, SP600125). RAD001 was purchased from Selleckchem and was 
administered 6-days per week by oral gavage (prepared in 1.5% NMP–98.5% PEG) at 
10mg/Kg. SAM486A was kindly provided by Novartis and prepared in water (in vitro) or 
saline solution (in vivo, 5 mg/Kg/day intraperitoneally Monday-Friday). U-13C5-L-
Methionine was purchased from Cambridge Isotope laboratories and administered 
intravenously at a final concentration of 100 mg/Kg in vivo and at 30 µg/mL in vitro (with 
dialyzed FBS). Doxycycline was purchased from Sigma and used at 500 ng/mL for over-
expression of YFP-PTEN, 100 ng/mL for silencing of AMD1 and 250 ng/mL for silencing 
of RAPTOR and TSC2. shRNAs against AMD1 were purchased from Sigma 
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(TRCN0000078462: sh3; TRCN0000078460: sh4, TRCN0000078461: sh5) and control 
shRNA sequence is included 
(CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTG)34. 
shRNAs against 4EBP1 and 2 were kindly provided by Dr. Nahum Sonenberg35. Sub-
cloning of shRNA AMD1 into pLKO-Tet-On vector was done introducing AgeI and EcoRI 
in the 5´end of top and bottom shRNA oligos respectively (TET-pLKO puro was a gift from 
Dr. Dmitri Wiederschain36, Addgene plasmid # 21915). Myc-AMD1-HA expressing vector 
was generated starting from the ORF obtained from PlasmID Harvard (https://
plasmid.med.harvard.edu; HsCD00321977) and cloned into a modified retroviral pLNCX 
vector that harbours BglII-SalI sites (cloned with BamHI-SalI). RNAi-resistant versions of 
AMD1 were generated using overlap extension PCR and cloned into a lentiviral backbone 
derived from vector pLenti-Cas9-blast (Cas9 removed; lentiCas9-Blast was a gift from Feng 
Zhang, Addgene #52962; Ref. 37) using HiFi Assembly Kit (NEB). The resulting vectors 
express AMD1-HA-2A-blast (WT or S229A) with AMD1-HA portion being excisable using 
BshT1-BamH1. The target of AMD1 shRNA#3 (5’-gtctccaagagacgtttcatt-3’) was changed to 
an RNAi-resistant version (5’-gtGAGcaaACGTAGAttTatCtt-3’). Cloning details are 
available upon request. All clones were sequence-validated. Site-directed mutagenesis for 
generation of AMD1S229A and AMD1S298A was performed using Agilent QuikChange II 
Site-Directed Mutagenesis Kit. YFP-PTEN-expressing lentiviral constructs were described 
in Ref.19.
Cellular and molecular assays
Cell number quantification was done with crystal violet29. Western blot was performed as 
previously described38, run in Nupage gradient precast gels (Life Technologies) in MOPS 
or MES buffer (depending on the proteins analysed; please note that the migration pattern of 
molecular weight markers varies in these two buffers). Anti-AMD1 was from Proteintech 
(11052-1-AP). Anti-RpS6S240/244, anti-RpS6, anti-S6KT389, anti-S6K, anti-LC3B, anti-
HSP90, anti-PTEN, anti-AKTS473, anti-AKT, anti-4EBP1 and anti-RAPTOR antibodies 
were from Cell Signalling Technologies. Anti-β-actin antibody was from Sigma and anti-
TSC2 from Thermo Scientific (MA5-15004). Densitometry-based quantification was carried 
out using ImageJ software. For half-life assays, DU145 cells stably expressing the indicated 
constructs were challenged with CHX (5 µg/mL) and protein was extracted at the indicated 
time points (cells were treated with vehicle – DMSO, MG132 – 5 µM, or Torin-1 – 250 nM 
– 120 minutes prior to CHX challenges when indicated). Anchorage independent growth 
assays were performed as previously described39, seeding 3000 (PC3) or 5000 (DU145) 
cells/well. RNA was extracted using NucleoSpin® RNA isolation kit from Macherey-Nagel 
(ref: 740955.240C). 1 μg of total RNA was used for cDNA synthesis using qScript cDNA 
Supermix from Quanta (ref. 95048). Quantitative Real Time PCR (q-RTPCR) was 
performed as previously described38. Applied biosystems TaqMan probes: Amd1/AMD1 
(Mm04207265, Hs00750876s1), β-ACTIN/β-Actin (Hs99999903_m1/Mm00607939_s1) 
and GAPDH/Gapdh (Hs02758991_g1/Mm99999915_g1). Universal Probe Library (UPL, 
Roche) probes: AMD1 (Probe 72, primer F: cagacctcctatgatgacctga; primer R: 
tcaggtcacgaattccactct), Odc1 (Probe 80, primer F: gctaagtcgaccttgtgagga; primer R: 
agctgctcatggttctcgat), ODC1 (Probe 34, primer F: aaaacatgggcgcttacact; primer R: 
tggaattgctgcatgagttg) and Mtap (Probe 12, primer F: ccatggcaaccgactatgat; primer R: 
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aaaccccatccactgacact). Foci assays were performed seeding 500 cells per well (6-well plate) 
and staining and counting them by crystal violet after 10 days. Lentiviral and retroviral 
transductions were performed as previously described34,38.
Kinase assay
Human AMD1 variants (C-terminal HA tag, non-processing mutant S229A; S298 (WT) or 
S298A; details available upon request) were prepared by overlapping PCR and cloned as 
BamH1-Not1 into pGEX-6P-1 (GE Healthcare). Sequence-confirmed clones were induced 
with 1mM IPTG for 16hrs at 20°C in C41 (DE3) pLysS (Lucigen). GST fusion proteins 
were purified first by glutathione affinity chromatography (eluted in 40mM reduced 
glutathione; 25mM Hepes pH 8; 50mM KCl; 0,1% BME buffer) and then were separated by 
a gel filtration chromatography. Proteins were concentrated by ultrafiltration (Vivaspin 5K 
MWCO cutoff; Sartorius) and used for kinase assays.
Endogenous mTORC1 complex was immunoprecipitated from HEK293 cells using anti-
Raptor antibody (S682B, 4th bleed, https://mrcppureagents.dundee.ac.uk/) coupled to 
Protein G Sepharose beads (Amersham). The cells were stimulated with IGF (50 ng/ml) for 
20 min prior to lysis in mTORC1 lysis buffer (40 mM HEPES pH 7.4, 120 mM NaCl, 1 mM 
EDTA, 0.3% (w/v), CHAPS, 10 mM Na-pyrophosphate, 10 mM Na-glycerophosphate, 1 
mM Na-orthovanadate, protease inhibitor cocktail (Roche)). The immunoprecipitate was 
washed twice with mTORC1 lysis buffer, containing 0.5 M NaCl, twice with mTORC1 lysis 
buffer and twice with mTORC1 kinase assay buffer (25 mM HEPES pH 7.4, 50 mM KCl). 
The substrates were added to immunoprecipitate in kinase assay buffer (15 μl) before adding 
the 10 μl of the ATP mixture (10 mM MnCl2, 100 μM ATP, 1 μCi 32P γ-ATP in kinase 
buffer). The reaction was carried out in thermomixer at 30ºC, for 30min and was terminated 
by adding the 4x sample buffer (NuPAGE LDS sample buffer, Life Technologies). The 
reaction mixture was loaded on gel. Dried gel was exposed to X-ray films (Amersham). 1 μL 
of reaction mixture was loaded on gel for immunoblot analysis. GST-S6KD236A (DU32609, 
https://mrcppureagents.dundee.ac.uk/) was purified from HEK293 cells pretreated with 0.1 
μM AZD-8055. The protein was purified using GST-Sepharose beads (Amersham) 
according to manufacturer’s instructions. Anti-Raptor (S682B, 4th bleed https://
mrcppureagents.dundee.ac.uk/), anti-phospho-S6K1 Thr389 (#9205, Cell Signaling 
Technologies), anti-GST (S902A, 3rd bleed, https://mrcppureagents.dundee.ac.uk/).
Immunohistochemical analysis
Histochemical analysis by Haematoxylin-Eosin, anti-RpS6S235/6, anti-AktS473 (Cell 
Signalling Technologies) and Pten (51-2400) immunostaining was performed as previously 
described40,41. Immunohistochemical analysis of AMD1 (Proteintech, dilution 1/100) was 
performed using DAKO envision Flex High pH (DAKO). The scoring system was based on 
the quantification of the % of cells negative, low (1+), medium (2+) or high (3+) 
immunoreactivity. Subsequently, H-score was calculated as follows: H = [percentage of cells 
1+] + [2 x (percentage of cells 2+)] + [3 x (percentage of cells 3+)]. Differential H score was 
calculated as follows: ΔH = H[on treatment] – H[pre-treatment].
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Metabolomic analysis
For in vitro metabolomic analysis, growing cells were washed with ammonium carbonate 
pH 7.4 and snap-frozen in liquid nitrogen. Metabolites were extracted from cells or tissues 
with cold 80/20 (v/v) methanol/water. Samples were then dried and stored at -80°C until MS 
analysis. High-throughput Time-Of-Flight analysis was conducted using flow injection 
analysis as previously described42. In short, samples were re-suspended and injected on an 
Agilent 1100 coupled with an Agilent 6520 QToF mass spectrometer with an electrospray 
ionization source. Mobile phase consisted of 60/40 methanol/water with 0.1% formic acid 
and was used to deliver 2 µL of each sample to the MS, flowing at 150 µL/min. Data was 
collected in positive mode with 4 GHz HiRes resolving power with internal lock masses. 
Data processing was conducted with Matlab R2010b. Relative cell number or protein 
amount was used for normalization.
Quantitative LC/MS was conducted as previously described43. A Thermo Accela 1250 
pump delivered a gradient of 0.025% heptafluorobutyric acid, 0.1% formic acid in water and 
acetonitrile at 400µL/min. Stationary phase was an Atlantis T3, 3 µm, 2.1x150 mm column. 
A QExactive Mass Spectrometer was used at 70.000 resolving power to acquire data in full-
scan mode. Data analysis was conducted in MAVEN44 and Spotfire. Peak areas derived 
from stable isotope labelling experiments have been corrected for naturally occurring isotope 
abundance.
For plasma 13C-methionine analysis, blood samples from mice were extracted at indicated 
times, transferred at room temperature to heparinized collection tubes and centrifuged at 
13,000 rpm 4ºC during 10 minutes. Plasma was transferred to fresh tubes and processed for 
UPLC-MS analysis. Briefly, to 40 µL aliquots of mouse plasma, 40 µL of water/0.15% FA 
was added. Subsequently, proteins were precipitated by addition of 120 µL of acetonitrile. In 
order to get optimum extraction, after addition of acetonitrile, the samples were sonicated 
for 10 minutes at 4ºC and agitated at 1,400 rpm for 30 min at 4ºC. Next, the samples were 
centrifuged at 14,000 rpm for 30 min at 4ºC. The supernatant was transferred to a fresh vial 
and measured with an UPLC system (Acquity, Waters, Manchester) coupled to a Time of 
Flight mass spectrometer (ToF MS, SYNAPT G2, Waters). A 2.1 x 100 mm, 1.7 µm BEH 
AMIDE column (Waters), thermostated at 40 °C. Solvent A (aqueous phase) consisted of 
99.5% water, 0.5% formic acid and 20 mM ammonium formate while solvent B (organic 
phase) consisted of 29.5% water, 70% MeCN, 0.5% formic acid and 1 mM Ammonium 
formate. In order to obtain a good separation of the analytes the following gradient was 
used: from 5% A to 50% A in 2.4 minutes in curved gradient ( #8, as defined by Waters), 
from 50% A to 99.9% A in 0.2 minutes constant at 99.9% A for 1.2 minutes, back to 5% A 
in 0.2 minutes. The flow rate was 0.250 mL/min and the injection volume was 2 µL. All 
samples were injected randomly and analytes were measured in enhanced duty cycle (EDC) 
mode, optimized for the mass of the analyte in question. Methionine and 13C5-methionine 
was measured in scan function 1 (EDC at 152), SAH and 13C4-SAH was measured in scan 
function 2 (EDC at 387), SAM and 13C5-SAM was measured in scan function 3 (EDC at 
402). Extracted ion traces were obtained for methionine (m/z = 150.0589), 13C5-methionine 
nine (m/z = 155.0756), SAH (m/z = 385.1294), 13C4-SAH (m/z =389.1428), SAM (m/z 
=399.145) and 13C5-SAM (m/z =404.1618) in a 20 mDa window and subsequently 
Zabala-Letona et al. Page 9
Nature. Author manuscript; available in PMC 2017 December 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
smoothed (2 points, 2 iterations) and integrated with QuanLynx software (Waters, 
Manchester). For quantitation, stock solutions of 10 mM in water for each of the analytes 
were prepared. Stock solutions were pooled and diluted in order to obtain a mixture 
including all analytes. The mixture was further diluted in water in order to obtain the 
concentrations as used in the calibration curve. The calibration range for all analytes 
included the following concentrations: 100, 50, 25, 10, 5, 2.5, 1, 0.5, 0.25, 0.1, 0.05 and 
0.025 µM.
Targeted metabolomics
Levels of dcSAM in cell cultures and tissues were analysed by ultra-high performance 
liquid-chromatography coupled to mass spectrometry (UPLC-MS). Briefly, extraction and 
homogenization was done in methanol/acetic acid (80/20 %v/v) Speed-vacuum-dried 
metabolites were solubilized in 100 µl of a mixture of water/acetonitrile (40/60 %v/v) and 
injected onto the UPLC/MS system (Acquity and SYNAPT G2, Waters, Manchester). The 
extracted ion traces were obtained for dcSAM (RT = 3.0’, m/z 355.16). Corrected signals 
were normalized to relative cell number.
Polysome profiling
Distribution of mRNAs across sucrose gradients was performed as described earlier45, 
except for minor modifications.
Phosphoproteomic analysis of AMD1
DU145 cells stably expressing Myc-AMD1-HA were plated in 2-3 150 mm plates per 
condition to ensure a final density no higher than 50-60% and sufficient protein amount to 
immunoprecipitate ectopic AMD1 (using agarose HA-beads, Sigma, according to 
manufacturers´ instructions). Cells were treated for 6 hours with rapamycin (20 nM) and 
Torin-1 (250 nM) prior to immunoprecipitation. Protein eluates from the 
immunoprecipitated samples were separated by SDS-PAGE. The bands corresponding to 
AMD1 and the proenzyme were visualized using Sypro-Ruby (Invitrogen), excised and in-
gel digested with trypsin. The resulting peptides were analyzed by LC-MS/MS using a LTQ 
Orbitrap Velos mass spectrometer (Thermo Scientific). Raw files were searched against a 
Uniprot Homo sapiens database (20,187 sequences) using Sequest-HT as the search engine 
through the Proteome Discoverer 1.4 (Thermo Scientific) software. Peptide identifications 
were filtered by Percolator at 1% FDR using the target-decoy strategy. Label-free 
quantification was performed with MaxQuant and extracted ion chromatograms for AMD1 
phosphopeptides were manually validated in Xcalibur 2.2 (Thermo).
Bioinformatic analysis
All the datasets used for the data mining analysis46–49 were downloaded from GEO, and 
subjected to background correction, log2 transformation and quartile normalization. In the 
case of using a pre-processed dataset, this normalization was reviewed and corrected if 
required.
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Statistical analysis
No statistics were applied to determine sample size. The experiments were not randomized. 
The investigators were not blinded to allocation during experiments and outcome 
assessment. Data analysed by parametric tests are represented by the mean ± s.e.m. of 
pooled experiments and for non-parametric tests median with interquartile range is depicted, 
unless otherwise stated. n values represent the number of independent experiments 
performed or the number of individual mice or patient specimens. For each independent in 
vitro experiment, at least three technical replicates were used and a minimum number of 
three experiments were performed to ensure adequate statistical power. ANOVA test was 
used for multi-component comparisons and Student's t-test for two component comparisons. 
In the in vitro experiments, normal distribution was confirmed or assumed (for n<5) Two-
tailed statistical analysis was applied for experimental design without predicted result, and 
one-tail for validation or hypothesis-driven experiments. The confidence level used for all 
the statistical analyses was of 0.95 (alpha value=0.05).
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Extended Data
Extended data Figure 1. Metabolomics characterization of murine and human prostate cancer.
a, Incidence of pathological alterations observed in Ptenpc+/+ and Ptenpc-/- mice. Number of 
mice as indicated. b, Representative immunohistochemical images of prostate tissue stained 
with Haematoxylin-Eosin (H&E), Pten, AktS473 and RpS6S235/6 from mice at three and six 
months of age (representative from 3 mice per condition). c, Experimental design of the 
Time-of-flight mass spectrometry (TOF-MS) metabolomics analysis. AP, anterior prostate; 
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DLP, dorsolateral prostate. d-e, Volcano plot (d) and principal component analysis (PCA, e) 
from altered metabolites in TOF-MS metabolomic analysis carried out in Ptenpc-/- and 
Ptenpc+/+ mouse prostate samples at the indicated age (6 months Ptenpc+/+ AP n=4 mice; rest 
of conditions n=5 mice). Grey dots: not significantly altered; red dots: significantly 
increased in Ptenpc-/- prostate extracts; blue dots: significantly decreased in Ptenpc-/- prostate 
extracts. f, Liquid chromatography/mass spectrometry (LC/MS) analysis of methionine 
cycle and polyamine pathway metabolites from Ptenpc-/- vs. Ptenpc+/+ mouse prostate 
samples at the indicated age (AP, 3 months n=5 mice; 6 months n=4 mice). Data are 
represented as median with interquartile range. g, LC/MS analysis of methionine cycle and 
polyamine pathway metabolites from PCa vs. BPH human specimens (6 prostate specimens 
per condition). Data are represented as median with interquartile range. p, p-value; *, 
p<0.05; **, p<0.01; ***; PIN: Prostatic Intraepithelial Neoplasia; LG-PIN: Low Grade PIN; 
HG-PIN: High Grade PIN; Focal Adc: Focal adenocarcinoma; BPH, benign prostate 
hyperplasia; PCa: Prostate Cancer; dcSAM: decarboxylated S-adenosylmethionine; SAM: 
S-adenosylmethionine; SAH: S-adenosylhomocysteine; MTA: 5´ Methylthioadenosine. 
Statistical analysis: One tail Mann-Whitney U test (f, g) was used for data analysis.
Extended data Figure 2. Metabolic tracing of 13C-Methionine in Pten-prostate specific knockout 
mice.
a, Plasma liquid chromatography/mass spectrometry (LC/MS) analysis of the indicated 
metabolite concentration after intravenous injection of U-13C5-L-Methionine (100mg/Kg) in 
C57BL/6 mice at 3 months of age (Time 0 min n=7 mice; Time 10 min/60 min n=6 mice). 
The unlabelled (M+0, 12C) and major labelled (13C, M+4 or M+5) metabolite concentration 
is presented in the histogram. Error values depict s.e.m. b, Experimental design of the 
U-13C5-L-Methionine (100mg/Kg) in vivo. c, Summary schematic of the alterations 
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observed in the metabolomic analysis in Ptenpc-/-. d, Fractional labeling of the indicated 
metabolites from Fig. 1e. Values are represented as median with interquartile range (1 hour –
upper panel - n=4; 10 hour – lower panel - n=3). p, p-value; Spm: Spermine; dcSAM: 
decarboxylated S-Adenosylmethionine; Spd: Spermidine; Met: Methionine; SAM: S-
Adenosylmethionine; SAH: S-Adenosylhomocysteine; MTA: 5´ Methylthioadenosine; 
ODC1: Ornithine Decarboxylase 1; SpdS: Spermidine Synthase; SpmS: Spermine Synthase; 
U-13C5-Met: L-Methionine labeled with13C in five carbons; 1h: prostate samples extracted 
after 1h pulse with U-13C5-L-Methionine; 10h: prostate samples extracted after 10 hour 
pulse with U-13C5-L-Methionine; FC: fold change; a.u.: arbitrary units.One tail Mann-
Whitney U test (d) was used for data analysis.
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Extended data Figure 3. Genetic modulation of AMD1 in prostate cancer cells.
a, Technical setup of anti-AMD1 antibody using the indicated constructs or shRNAs in 
DU145 cells. AMD1S229A mutant lacks processing ability and is expressed exclusively as a 
pro-enzyme (representative western blot out of 3 independent experiments). b, Schematic 
representation of tagged ectopic AMD1 processing. c, Impact of ectopic Myc-AMD1-HA 
expression on foci number in DU145 cells in vitro (n=3 independent experiments). d-f, 
Impact of ectopic Myc-AMD1-HA expression on tumour volume (d, n=8 tumours per 
condition), AMD1 protein levels (e, n=3 tumours per condition) and dcSAM abundance (f, 
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n=5 tumours per condition) in DU145 xenografts grown for 43 days. Data in d is represented 
as box and whisker plot. Panel f shows a dot plot with the median and the interquartile 
range. g-o, Effect of constitutive silencing of AMD1 (g, i, mRNA levels in g-i and protein 
expression in h-j) on cell number (k, n), anchorage-independent growth (l, o) and dcSAM 
abundance (m) with two different hairpins in DU145 (g, h, k, l, m) and PC3 (i, j, n, o) cells 
(n=3-4 independent experiments as indicated by dots). Values are represented as mean with 
s.e.m. p, Effect of doxycycline-inducible (100 ng/mL) AMD1 silencing on cell number in 
DU145 cells (sh3 n=3; sh4-5 n=4 independent experiments as indicated by dots). q-s, Impact 
of AMD1 inducible silencing in tumor volume from DU145 xenografts (Tumours analysed: 
sh3 No Dox, n=12; sh3 Dox, n=14; sh4 No Dox, n=10; sh4 Dox, n=7; sh5 No Dox, n=10; 
sh5 Dox, n=11). Values are represented as box and whisker plot. t, Impact of AMD1 
inducible silencing in dcSAM abundance in DU145 xenografts from panels q-s (n=5 
tumours). Values are represented as median with interquartile range. u-v, Dose-dependent 
effect of doxycycline on cell number in DU145 (u) and PC3 (v) cells (cell number measured 
at day 6) (n=3 independent experiments as indicated by dots). shSC: scramble short hairpin; 
sh3 and sh4: two different short-hairpins targeting AMD1; dox: doxycycline; p, p-value; *, 
p<0.05; **, p<0.01; ***, p<0.001. Red asterisk in western blot indicates non-specific band. 
Dashed line indicates cell number in shC-transduced cells. Statistic test: one tail T-test (c, g, 
i, k-p, u-v), and one-tail Mann Whitney U test (d, f, q-t).
Zabala-Letona et al. Page 16
Nature. Author manuscript; available in PMC 2017 December 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Extended data Figure 4. Genetic and pharmacological manipulation of AMD1 in prostate cancer 
cells.
a-c, DU145 cells carrying doxycycline-inducible shRNA against AMD1 (sh3) were 
transduced with empty (Mock), sh3-resistant wildtype (AMD1sh3R) or processing-deficient 
(AMD1S229A,sh3R) AMD1 constructs. AMD1 protein (a, representative experiment out of 4), 
dcSAM abundance (b) and cell number expression (c) in the aforementioned cells (n=4 
independent experiments as indicated by dots). Asterisks indicate significant differences 
compared to the corresponding DU145 cells in the absence of doxycycline, and hash 
indicates significant differences in the indicated comparison. Values are represented as mean 
with s.e.m. d, Effect of 5´ Methylthioadenosine (MTA, 25 µM) on AMD1 silencing (sh3)-
elicited antiproliferative activity. MTA was administered at day 0 and cells were analyzed at 
day 3 (n=3 independent experiments as indicated by dots). e, Mtap gene expression levels in 
Ptenpc+/+and Ptenpc-/- mice at the indicated time points (see Extended data Fig. 1a) (3 
months n=3 mice; 6 months n=6 mice). Values are represented as median with interquartile 
range. f, MTAP gene expression analysis in publicly available datasets (see methods; N: 
Normal, PCa: Prostate cancer; Number of patients analised: Taylor et al., Normal n=29, PCa 
n=150; Grasso et al., Normal n=12, PCa n=76; Lapointe et al., Normal n=9, PCa n=17). g-h, 
Effect of pharmacological AMD1 inhibition with SAM486A on cell number (g and left h 
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panels ; DU145 n=5; PC3 n=4 independent experiments as indicated by dots), and 
anchorage-independent growth (righ h panel, n=3 independent experiments as indicated by 
dots) in PC3 or DU145 cells as indicated. Data is represented as mean with s.e.m. i, Effect of 
pharmacological AMD1 inhibition with SAM486A in established DU145 xenograft tumor 
volume (Vehicle n=11 tumours, SAM486A n=10 tumours). Values are represented as box 
and whisker plot. j-k, Effect of pharmacological AMD1 inhibition with SAM486A in 
activated T CD4 cell number (96h, j, n=3 independent experiments as indicated by dots) or 
IL-2 production (k, n=3-6 independent experiments as indicated by dots). a.u.: arbitrary 
units, Dox: doxycycline,p, p-value; */#, p<0.05; **/##, p<0.01; ***, p<0.001. Dashed line 
indicates cell number (g, h) or IL-2 abundance (k) in vehicle-treated cells. Statistic 
test:Student T-test (b, c, d, f,g, h, j, k) and one tail Mann Whitney test (e, i).
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Extended data Figure 5. PTEN-PI3K-mTORC1-dependent regulation of AMD1 in prostate 
cancer.
a-b, Amd1 protein quantification from Fig. 3a (a, n=3 mice) and mRNA expression (b, 
n=5-6 mice as indicated by dots) in Ptenpc-/- and Ptenpc+/+ mice of the indicated age. Data 
are represented as median with interquartile range. c, AMD1 gene expression analysis in 
publicly available datasets (see methods; N: Normal, PCa: Prostate cancer; Number of 
patients analysed: Taylor et al., Normal n=29, PCa n=150; Grasso et al., Normal n=12, PCa 
n=76; Lapointe et al., Normal n=9, PCa n=17). d, Representative western blot showing the 
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expression of the indicated proteins upon doxycycline-inducible expression (24h) of YFP-
PTENWT or catallitically inactive YFP-PTENC124S in PTEN-deficient LNCaP prostate 
cancer cells (n=3 independent experiments). e, Schematic representation of the PI3K 
signaling pathway and the pharmacological/genetic tools employed in this study. f, 
ProAMD1 and AMD1 protein quantification from Fig. 3b (sample number as indicated by 
dots). g, AMD1 gene expression upon treatment (24h) with vehicle (V, DMSO), Rapamycin 
(R, 20nM) and Torin-1 (T, 250nM for PC3 and DU145, 125nM for LNCaP) (LNCaP n=8 for 
T; R and n=6 for PC3 and DU145 n=6 independent experiments as indicated by dots). 
Values are represented as mean with s.e.m. h, Representative western blot analysis of AMD1 
levels upon 24-hour treatment of DU145 cells with vehicle (V), Torin-1 (mTORC1/2 
inhibitor, T; 250 nM), PD032901 (ERK-MAPK inhibitor, PD; 100 nM), SP600125 (JNK-
SAPK inhibitor, SP; 10 µM) and SB203580 (p38-MAPK inhibitor, SB; 5 µM) (n=3 
independent experiments). i, Impact of inducible RAPTOR silencing in DU145 cells on 
proAMD1 protein levels (doxycycline-induced, 250 ng/mL) (Representative experiment out 
of n=6). j, Impact of inducible TSC2 silencing in DU145 cells on proAMD1 protein levels 
(doxycycline-induced, 250 ng/mL) (Representative experiment out of n=6). a.u.: arbitrary 
units, Dox: doxycycline, N: Normal, PCa: Prostate cancer; p, p-value; *, p<0.05; **, p<0.01; 
***, p<0.001. Red asterisk in western blot indicates non-specific band. Arrows indicate 
specific immunoreactive bands. Statistic test: Student T-test (c, f, g) and Mann Whitney test 
(a, b).
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Extended data Figure 6. mTORC1-dependent AMD1 regulation in vivo.
a, Effect of spermidine (Spd, 0.75 µM) on PC3 cell number upon rapamycin treatment (1 
nM, outcome measured 72h after treatment). Drugs were administered at day 0 and only Spd 
was additionally administered at day 1 (n=4 independent experiments as indicated by dots). 
b,Effect of RAD001 treatment on prostate pathological features and mTORC1 activity 
(Haematoxylin-Eosin - H&E - and RpS6S235/6 staining by IHC) (n=3 mice). c, ProAmd1 
and Amd1 protein abundance quantification from Fig. 3e (right panel; number of mice as 
indicated by dots). d, Representative immunohistochemical images of prostate tissue from 
wildtype or TRAMP mice (+/T, 28-32 weeks old) stained with H&E (top panels) and 
RpS6S235/6 (lower panels, Ptenpc+/+ and Ptenpc-/- prostate tissues are presented as 
comparison of the RpS6 phosphorylation levels) (n=3 mice). e, Evaluation of AMD1 
expression by western blot in prostate tissues from wildtype or TRAMP mice (+/T, 28-32 
weeks old) (n=4 mice). a.u.: arbitrary units, p, p-value; *, p<0.05; **, p<0.01. Arrows 
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indicate specific immunoreactive bands. Statistic test: Student T-test (a) and Mann Whitney 
test (c, e).
Extended data Figure 7. Contribution of mTORC1 effector pathways and targets on the 
regulation of AMD1.
a, ODC1 gene expression upon treatment (24h) of Vehicle (V, DMSO), Rapamycin (R, 20 
nM) and Torin-1 (T, 250 nM for PC3 and DU145, 125 nM for LNCaP) in PC3, LNCaP and 
DU145 cells (n=5 independent experiments as indicated by dots).Values are represented as 
mean with s.e.m. b, Putrescine abundance upon treatment (24h) of Vehicle (V, DMSO), 
Rapamycin (R, 20 nM) and Torin-1 (T, 250 nM) in DU145 and PC3 cells (n=3 independent 
experiments as indicated by dots). Values are represented as mean with s.e.m. c, Odc1 gene 
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expression in 3-month and 6-month old Ptenpc+/+ and Ptenpc-/- mice (n=3-6 as indicated by 
dots). Values are represented as median with interquartile range. d, Putrescine abundance in 
12 week-old Ptenpc-/- mice upon treatment with vehicle (V) or RAD001 (10 mg/kg, 6-days 
per week) for four weeks (n=5 mice). Values are represented as mean with s.e.m. e, 
Representative western blot (n=3 independent experiments) depicting the changes in 
expression of the indicated proteins upon 24 hour treatment of DU145 cells with Rapamycin 
(R, 20 nM) and/or DFMO (an inhibitor of ODC1, 50 µM) with the corresponding vehicles. f, 
Representative westenblot showing LC3 lipidation in Hydroxycloroquine (HCQ)-treated 
(6h) DU145 and PC3 cells, as a readout of macro-autophagy (n=3 independent 
experiments). Arrow indicates LC3-II. g, For the analysis of translation initiation, polysome 
profiling analysis of AMD1 and L11 as positive control in DU145 cells treated with vehicle 
or Rapamycin (20 nM, 8h) is shown. Error bars depicts standard deviation from technical 
replicates. h, Effect of pharmacological p70S6K inhibition with PF4708671 (10 µM) in 
DU145 cells on AMD1 protein expression (Representative experiment out of 5). i, Effect of 
4EBP1/2 silencing on proAMD1 and AMD1 protein expression (upper panel) 
(Representative experiment out of 3). Lower panels show 4EBP1 (n=5 independent 
experiments) and 4EBP2 (n=4 independent experiments) gene expression in shRNA-
transduced DU145 cells. a.u.: arbitrary units; DFMO, Difluoromethylornithine; Rapa, 
Rapamycin; HCQ, Hydroxychloroquine; p, p-value; *, p<0.05; **, p<0.01; ***, p<0.001. 
Red asterisk in western blot indicates non-specific band. Arrows indicate specific 
immunoreactive bands. Statistic test: Student T-test (a, b, i) and Mann Whitney U test (c, d).
Zabala-Letona et al. Page 23
Nature. Author manuscript; available in PMC 2017 December 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Extended data Figure 8. Regulation of proAMD1 stability by mTORC1.
a, ProAmd1 (left) and Amd1 (right) protein abundance quantification from Fig. 4a (n=3 
independent experiments as indicated by dots). b, Representative western blot of DU145 
cells expressing Ser-229-Ala (S229A) mutant Myc-AMD1-HA treated with vehicle or 
Torin-1 (250 nM, 6h) in the presence or absence of MG132 (5 µM, 6h) (n=3 independent 
experiments). Quantification is provided in right panel. c, Representative MS/MS spectrum 
of the TVLASPQKIEGFK peptide in proAMD1 and AMD1, in which phosphorylation was 
unambiguously assigned to S298 residue. d, Calculated areas under the curves from 
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extracted ion chromatogram (XIC) of the TVLASPQKIEGFK peptide for phosphorylated 
(highlighted in red in the sequence, left panel) and total (right panel) proAMD1. e, 
Calculated areas under the curves from extracted ion chromatogram (XIC) of the 
TVLASPQKIEGFK peptide for phosphorylated (highlighted in red in the sequence, middle 
panel) and total (right panel) AMD1. f, Schematic representation of the working hypothesis 
of proAMD1 regulation by mTORC1-dependent phosphorylation. g, Effect of Torin (250 
nM) on proAMD1 and AMD1 protein at different time points in Myc-AMD1-HA-
expressing DU145 cells (representative western blot out of 3 independent experiments, right 
panel presents the densitometric quantification). Error bars depict s.e.m. h-i, Representative 
western blot depicting the stability of ectopic proAMD1 and AMD1 in DU145 cells 
challenged with vehicle (V) or Torin-1 (T, 250 nM, 2h) upon CHX treatment (densitometry 
of proAMD1 and AMD1 levels is represented in right panels, h) and half-life reduction in 
proAMD1 (i) (n=4 independent experiments). j-k, Representative western blot depicting the 
stability of S229A mutant AMD1 construct in DU145 cells challenged with vehicle (V) or 
Torin-1 (T, 250 nM, 2h) upon CHX treatment (densitometry of proAMD1 is represented in 
right panels, j) and half-life reduction in proAMD1 (k) (n=3 independent experiments). Data 
are represented as mean with s.e.m. a.u.: arbitrary units; CHX, Cycloheximide; n.s.: not 
significant p, p-value; *, p<0.05; **, p<0.01; ***, p<0.001. Statistic test: Student T-test.
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Extended data Figure 9. Contribution of proAMD1 phosphorylation downstream mTORC1 to 
the stability of the enzyme.
a-b, Representative western blot depicting the stability of WT and S298A phospho-mutant 
AMD1 constructs in DU145 cells upon cycloheximide treatment (densitometry of proAMD1 
and AMD1 is represented in right panels, a) and half-life reduction in proAMD1 (b) (n=3 
independent experiments). Data are represented as mean with s.e.m. c, Representative 
western blot depicting the stability of S298A mutant AMD1 construct in DU145 cells 
challenged with vehicle (V) or MG132 (5 µM) upon CHX treatment (densitometry of 
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proAMD1 is represented in right panel, n=3 independent experiments). Data are represented 
as mean with s.e.m. d, mTORC1 kinase activity (by means of RAPTOR 
immunoprecipitation from HEK293 cells) on GST-proAMD1S229A or GST-
proAMD1S229A/S298A, using bacteria-purified proteins. GST-p70S6K is presented as 
positive control. AZD8055 is employed as control of mTORC1 inhibition. e, Correlation 
analysis between p70S6KThr389 and AMD1 densitometry values in PCa specimens from Fig. 
4c (n=15 patient specimens). f, Quantification of AMD1 immunoreactivity in response to 
everolimus in tumor biopsies, based on the ΔH score (n=14 specimen pairs). g, Box and 
whisker plot of the immunoreactivity of mTOR downstream effectors (AKTS473, 
RpS6S240/244, 4EBP1/2T70, eIF4GS1108) in cancer patients with (ΔH score for KI67 < 0; n=6 
specimen pairs) or without (ΔH score for KI67 ≥ 0; n=4 specimen pairs) anti-proliferative 
tumour response upon everolimus treatment. h, Schematic representation of the main 
findings of this study. Met, methionine; SAM, S-Adenosylmethionine; dcSAM, 
decarboxylated S-Adenosylmethionine; Orn, ornithine; Put, putrescine; Spd, spermidine; 
Spm, spermine; AMD1, S-Adenosylmethionine decarboxylase 1; ODC1, ornithine 
decarboxylase 1; PIP2, Phosphatidyl Inositol biphospate; PIP3, Phosphatidyl Inositol 
triphospate; a.u.: arbitrary units; ΔH: Differential H-Score (ΔH = H[on treatment] – 
H[pre-treatment]); p, p-value; CHX, Cycloheximide; *, p<0.05; **, p<0.01; n.s.: not 
significant. Arrows indicate specific immunoreactive/autoradiographic bands. Statistic test: 
one tail Student T-test (a, b, c), two-tail Mann Whitney test (g) and Spearman correlation 
analysis (e).
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Figure 1. Integrative metabolomics in prostate cancer reveals a rewiring from methionine 
metabolism towards polyamine synthesis.
a-b, VENN diagram (anterior prostate - AP - and dorsolateral prostate - DLP, a), and 
Waterfall plot (b) from the analysis of altered metabolites in TOF-MS metabolomic analysis 
carried out in Ptenpc-/- and Ptenpc+/+ (6 months Ptenpc+/+ AP n=4 mice; rest of conditions 
n=5 mice) mouse prostate samples at the indicated age. Values in (b) represent the average 
of the Log (Fold change) with the s.e.m. of the two lobes and two time points (3 and 6 
months of age) per metabolite. c, Incorporation of 13C from intravenously injected U-13C5-
L-Methionine (100 mg/Kg) into the indicated metabolites at 3 months of age (AP). Peak 
area refers to natural abundance-corrected values (n=4 mice at 1 hour; n=3 mice at 10 
hours). Data are represented as median with interquartile range. Blue dots: 13C; white 
dots: 12C; 1h: prostate samples extracted after 1-hour pulse with U-13C5-Methionine; 10h: 
prostate samples extracted after 10-hour pulse with U-13C5-Methionine. d, dcSAM/SAM 
ratios from Extended data Fig. 1f (n=4 as indicated by dots). e, dcSAM/SAM ratio from 
Extended data Fig. 1g (n=6 as indicated by dots). f, dcSAM/SAM ratio from Fig. 1c at 1 
hour (n=4 as indicated by dots). a.u.: arbitrary units; 3M/6M: 3 Months / 6 Months; dcSAM: 
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decarboxylated S-Adenosylmethionine; MTA: 5´ methylthioadenosine; SAM: S-
Adenosylmethionine; SAH: S-Adenosylhomocysteine; Met: methionine; p, p-value; *, 
p<0.05; **, p<0.01. One tail (c-f) Mann-Whitney U test was used for data analysis.
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Figure 2. Genetic and pharmacological AMD1 modulation affects prostate cancer oncogenicity.
a-c, Impact of ectopic Myc-AMD1-HA expression (a, representative from 3 independent 
experiments) on dcSAM abundance (b, n=5 independent experiments) and anchorage-
independent growth (c, n=4 independent experiments) in DU145 cells in vitro. Data are 
represented as mean with s.e.m. d, Impact of ectopic Myc-AMD1-HA expression on tumor 
weight in DU145 xenografts grown for 43 days (Mock n=8 tumours; Myc-AMD1-HA n=7 
tumours). Data in is represented as box and whisker plot. e-g, Effect of doxycycline-
inducible (100 ng/mL) AMD1 silencing (sh3-5) on AMD1 protein expression (e, 
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representative from 3 independent experiments), dcSAM abundance (f, n=3 independent 
experiments) and anchorage-independent growth (g, n=4 independent experiments) in 
DU145 cells. Dash line indicates relative cell number of non-induced cells. Data are 
represented as mean with s.e.m. h, Impact of inducible AMD1 silencing on tumor growth 
rate of established DU145 xenografts (Tumour number: sh3 No Dox, n=12; sh3 Dox, n=14; 
sh4 No Dox, n=10; sh4 Dox, n=7; sh5 No Dox, n=10; sh5 Dox, n=11). Growth rate was 
inferred from the linear regression calculated for the progressive change in tumor volume of 
each individual tumor during the period depicted in Extended data Fig. 3q-s. Data is 
represented as box and whisker plot. i-j, Effect of pharmacological AMD1 inhibition with 
SAM486A on anchorage-independent growth (i, n=3 independent experiments) and dcSAM 
abundance (j, n=3 independent experiments) in DU145 cells. Dash line indicates relative cell 
number of vehicle-treated cells. Data is represented as mean with s.e.m. k, Impact of 
SAM486A treatment for 14 days (5mg/Kg/day, 5 days per week) on tumor growth rate of 
established DU145 xenografts (Vehicle, n=11 tumours; SAM4856A, n=10 tumours). Growth 
rate was inferred from the linear regression calculated for the progressive change in tumor 
volume of each individual tumor during the period depicted in Extended data Fig. 4i. Data is 
represented as box and whisker plot. a.u.: arbitrary units; dcSAM: decarboxylated S-
adenosylmethionine; - Dox: non-induced condition; + Dox: doxycycline-induced (100 
ng/mL) condition; Mock: Empty vector; Myc-AMD1-HA: Myc and HA-tagged AMD1 
ectopic expression, sh: short hairpin RNA. p, p-value; *, p<0.05; **, p<0.01, ***, p<0.001. 
Statistic test: one tail Student T-test was used for cell line data analysis (b, c, f, g, i, j) and 
one tail Mann-Whitney U test for xenografts (d, h, k).
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Figure 3. mTORC1 regulates AMD1 expression, dcSAM production and polyamine dynamics.
a, Amd1 protein abundance in Ptenpc-/- and Ptenpc+/+ of the indicated age (n=3 mice). 
AKTS473 is shown as control of PI3K pathway over-activation. b, Representative western 
blot (out of 3) depicting the changes in expression of the indicated proteins upon 24 hour 
treatment of PC3, DU145 and LNCaP cells with vehicle (V, DMSO), rapamycin (R, 20 nM) 
and Torin-1 (T, 250 nM for PC3 and DU145, 125 nM for LNCaP). c, dcSAM abundance in 
PC3 (n=4-5 independent experiments as indicated by dots), LNCaP (n=5 independent 
experiments) and DU145 (n=5 independent experiments), upon 24 hour treatment with 
vehicle (V, DMSO), rapamycin (R, 20 nM) and Torin-1 (T, 250 nM for PC3 and DU145, 125 
nM for LNCaP). Data are represented as mean with s.e.m. d, Incorporation of 13C from 
U-13C5-L-Methionine (2h pulse) into the indicated metabolites after 30 hour treatment with 
vehicle (V, DMSO) or rapamycin (R, 20 nM) in DU145 cells (n=3 independent 
experiments). Data are represented as mean with s.e.m. e-f, Effect of 4-week RAD001 
treatment on mTORC1 activity (RpS6S240/4) and Amd1 protein expression (e, n=3 mice), 
and dcSAM abundance (f, n=5 mice) in prostate tissue extracts from Ptenpc-/- mice. Data in 
(f) are represented as mean with s.e.m. a.u.: arbitrary units; 3Mo: 3 month-old mouse 
prostate analysis; 6Mo: 6 month-old prostate analysis; V: Vehicle; dcSAM: decarboxylated 
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S-adenosylmethionine; Spd 13C (M+3): Spermidine labeled in three carbons; Spm 13C (M
+3): Spermine labeled in three carbons; Spm 13C (M+6): Spermine labeled in six carbons; p, 
p-value; *, p<0.05; **, p<0.01; ***, p<0.001. Red asterisk in western blot indicates non-
specific band; arrow: specific band. Statistic test: one tail Student T-test (c, d, f) was used.
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Figure 4. mTORC1 regulates AMD1 stability and this molecular regulation is recapitulated in 
vivo.
a, Representative western blot (out of 3) of DU145 cells expressing Myc-AMD1-HA treated 
with vehicle or Torin-1 (250 nM, 6h) in the presence or absence of MG132 (5 µM, 6h). b, 
Extracted ion chromatogram (XIC) of the TVLASPQKIEGFK phosphorylated proAMD1 
peptide. c, Western blot analysis (individual tissue specimens are presented) of AMD1 and 
p70S6KThr389 in prostate tissue samples of BPH and PCa. Densitometry values of AMD1 
and p70S6KThr389 are provided below the scans (corrected by HSP90 immunoreactivity). 
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p70S6KThr389 PCa status was defined as normal (Nor; PCaS6K Nor) when the densitometry 
values of the PCa sample were lower than [mean + standard deviation] of the BPH 
specimens, and high (Hi, PCaS6K Hi) when the densitometry values of the PCa samples were 
greater than [mean + standard deviation] of the BPH specimens. The statistical analysis 
related to differential AMD1 immunoreactivity was performed analysing separately 
PCaS6K Nor (n=7 specimens) and PCaS6K Hi (n=8 specimens) vs. the BPH specimens (n=6 
specimens). d, Representative AMD1 immunoreactivity images of three patient specimens 
before (pre-treatment) or after (on treatment) therapy with everolimus (n=14 specimen 
pairs). e, Box and whisker plot of the immunoreactivity of KI67 and AMD1 in cancer 
patients with (ΔH score for KI67 < 0) or without (ΔH score for KI67 ≥ 0) anti-proliferative 
tumour response upon everolimus treatment. a.u.: arbitrary units; ΔH: Differential H-Score 
(ΔH=[H score on-therapy] - [H score pre-therapy]); p, p-value; BPH, benign prostate 
hyperplasia; PCa, prostate cancer; *, p<0.05; **, p<0.01. Arrows indictate specific 
immunoreactive bands. Red asterisk in western blot indicates non-specific band. Statistic 
test: Mann Whitney test (c, e).
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